SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access